Cargando…
Differential Expression of BARD1 Isoforms in Melanoma
Melanoma comprises <5% of cutaneous malignancies, yet it causes a significant proportion of skin cancer-related deaths worldwide. While new therapies for melanoma have been developed, not all patients respond well. Thus, further research is required to better predict patient outcomes. Using long-...
Autores principales: | McDougall, Lorissa I., Powell, Ryan M., Ratajska, Magdalena, Lynch-Sutherland, Chi F., Hossain, Sultana Mehbuba, Wiggins, George A. R., Harazin-Lechowska, Agnieszka, Cybulska-Stopa, Bożena, Motwani, Jyoti, Macaulay, Erin C., Reid, Glen, Walker, Logan C., Ryś, Janusz, Eccles, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927127/ https://www.ncbi.nlm.nih.gov/pubmed/33672422 http://dx.doi.org/10.3390/genes12020320 |
Ejemplares similares
-
Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures
por: Hossain, Sultana Mehbuba, et al.
Publicado: (2022) -
Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability
por: Pilyugin, Maxim, et al.
Publicado: (2016) -
Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
por: Hossain, Sultana Mehbuba, et al.
Publicado: (2021) -
Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012) -
Expression of BARD1 β Isoform in Selected Pediatric Tumors
por: Jasiak, Anna, et al.
Publicado: (2021)